GLP-1, a powerful physiological incretin: an update

Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biological regulators and homeostatic agents 2018-09, Vol.32 (5), p.1171-1176
Hauptverfasser: Malik, J, Roohi, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1176
container_issue 5
container_start_page 1171
container_title Journal of biological regulators and homeostatic agents
container_volume 32
creator Malik, J
Roohi, N
description Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2122578433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2122578433</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-cf2c6a70a1b063f3a9e562a96add4881ee584a09cbae4d2ac8ebbdc50022f2173</originalsourceid><addsrcrecordid>eNo1j01LxDAUAHNQ3HX1L0iOHiwkeWnTeJNFd4WCHhS8ldfkVSP9iE2L7L9XcD3NZRiYE7YWYCGzRr-t2HlKn0Jo0MacsRUIAK2FXTPYVc-ZvOHI4_hNU7t0PH4cUhi78T047HgY3ERzGG45DnyJHme6YKctdokuj9yw14f7l-0-q552j9u7KotKyjlzrXIFGoGyEQW0gJbyQqEt0HtdlpIoLzUK6xok7RW6kprGu1wIpVolDWzY9V83TuPXQmmu-5AcdR0ONC6pVlKp3JQa4Fe9OqpL05Ov4xR6nA71_yj8ABRITSU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2122578433</pqid></control><display><type>article</type><title>GLP-1, a powerful physiological incretin: an update</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Malik, J ; Roohi, N</creator><creatorcontrib>Malik, J ; Roohi, N</creatorcontrib><description>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</description><identifier>ISSN: 0393-974X</identifier><identifier>PMID: 30334409</identifier><language>eng</language><publisher>Italy</publisher><subject>Diabetes Complications - drug therapy ; Diabetes Complications - metabolism ; Diabetes Complications - prevention &amp; control ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - metabolism ; Glucagon-Like Peptide 1 - physiology ; Glucagon-Like Peptide-1 Receptor - metabolism ; Humans ; Incretins - physiology ; Insulin-Secreting Cells - cytology ; Insulin-Secreting Cells - metabolism</subject><ispartof>Journal of biological regulators and homeostatic agents, 2018-09, Vol.32 (5), p.1171-1176</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30334409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malik, J</creatorcontrib><creatorcontrib>Roohi, N</creatorcontrib><title>GLP-1, a powerful physiological incretin: an update</title><title>Journal of biological regulators and homeostatic agents</title><addtitle>J Biol Regul Homeost Agents</addtitle><description>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</description><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Complications - metabolism</subject><subject>Diabetes Complications - prevention &amp; control</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Glucagon-Like Peptide 1 - physiology</subject><subject>Glucagon-Like Peptide-1 Receptor - metabolism</subject><subject>Humans</subject><subject>Incretins - physiology</subject><subject>Insulin-Secreting Cells - cytology</subject><subject>Insulin-Secreting Cells - metabolism</subject><issn>0393-974X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAUAHNQ3HX1L0iOHiwkeWnTeJNFd4WCHhS8ldfkVSP9iE2L7L9XcD3NZRiYE7YWYCGzRr-t2HlKn0Jo0MacsRUIAK2FXTPYVc-ZvOHI4_hNU7t0PH4cUhi78T047HgY3ERzGG45DnyJHme6YKctdokuj9yw14f7l-0-q552j9u7KotKyjlzrXIFGoGyEQW0gJbyQqEt0HtdlpIoLzUK6xok7RW6kprGu1wIpVolDWzY9V83TuPXQmmu-5AcdR0ONC6pVlKp3JQa4Fe9OqpL05Ov4xR6nA71_yj8ABRITSU</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Malik, J</creator><creator>Roohi, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>GLP-1, a powerful physiological incretin: an update</title><author>Malik, J ; Roohi, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-cf2c6a70a1b063f3a9e562a96add4881ee584a09cbae4d2ac8ebbdc50022f2173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Complications - metabolism</topic><topic>Diabetes Complications - prevention &amp; control</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Glucagon-Like Peptide 1 - physiology</topic><topic>Glucagon-Like Peptide-1 Receptor - metabolism</topic><topic>Humans</topic><topic>Incretins - physiology</topic><topic>Insulin-Secreting Cells - cytology</topic><topic>Insulin-Secreting Cells - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malik, J</creatorcontrib><creatorcontrib>Roohi, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biological regulators and homeostatic agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malik, J</au><au>Roohi, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GLP-1, a powerful physiological incretin: an update</atitle><jtitle>Journal of biological regulators and homeostatic agents</jtitle><addtitle>J Biol Regul Homeost Agents</addtitle><date>2018-09</date><risdate>2018</risdate><volume>32</volume><issue>5</issue><spage>1171</spage><epage>1176</epage><pages>1171-1176</pages><issn>0393-974X</issn><abstract>Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful regulator of physiological functions. Mainly (GLP-1) receptors are expressed in lungs, α and β cells of pancreatic islets and the nervous system. Peripheral tissues, gastrointestinal tract and extra pancreatic tissues i.e., vascular smooth muscle, kidney and heart, also contain high affinity receptors for GLP-1. The aim of this systematic review was to gather the available published evidence of the functions performed by GLP-1 through the activation of its receptor in various organs. This review suggest that GLP-1 receptor signaling helps prevent beta cell apoptosis and conserve function and morphology of human islet. The effect of GLP-1 signaling in weight loss in diabetic patients was proved by previous studies. The long term use of GLP-1 receptor agonists reduces cardiovascular and renal complications in diabetic patients. Significant evidence was found in previous literature for its effect on pancreatic secretions. The secretions of many enzymes and hormones, such as trypsin, lipase and glucagon, inhibited significantly while the increase in levels of insulin and somatostatin was reported in many studies. GLP-1 has a prominent role in cardiac functioning and increases the heart rate considerably. Based on the vast impact of GLP-1 on physiological functions, many GLP-1 receptor agonists can be made that can increase the healthy life span.</abstract><cop>Italy</cop><pmid>30334409</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0393-974X
ispartof Journal of biological regulators and homeostatic agents, 2018-09, Vol.32 (5), p.1171-1176
issn 0393-974X
language eng
recordid cdi_proquest_miscellaneous_2122578433
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Diabetes Complications - drug therapy
Diabetes Complications - metabolism
Diabetes Complications - prevention & control
Diabetes Mellitus - drug therapy
Diabetes Mellitus - metabolism
Glucagon-Like Peptide 1 - physiology
Glucagon-Like Peptide-1 Receptor - metabolism
Humans
Incretins - physiology
Insulin-Secreting Cells - cytology
Insulin-Secreting Cells - metabolism
title GLP-1, a powerful physiological incretin: an update
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A10%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GLP-1,%20a%20powerful%20physiological%20incretin:%20an%20update&rft.jtitle=Journal%20of%20biological%20regulators%20and%20homeostatic%20agents&rft.au=Malik,%20J&rft.date=2018-09&rft.volume=32&rft.issue=5&rft.spage=1171&rft.epage=1176&rft.pages=1171-1176&rft.issn=0393-974X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2122578433%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2122578433&rft_id=info:pmid/30334409&rfr_iscdi=true